Synthetic lethal approaches to breast cancer therapy

[1]  J. Dungan.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2011 .

[2]  A. Ashworth,et al.  A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer , 2010, Clinical Cancer Research.

[3]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[4]  B. Karlan,et al.  Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Mark Robson,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2010, The Lancet.

[6]  A. Tutt,et al.  Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial , 2010, The Lancet.

[7]  Yiyu Dong,et al.  Synthetic lethality through combined Notch-epidermal growth factor receptor pathway inhibition in basal-like breast cancer. , 2010, Cancer research.

[8]  Ricky A. Sharma,et al.  Molecular and Cellular Pathobiology Cancer Research Poly ( ADP-Ribose ) Polymerase Is Hyperactivated in Homologous Recombination – Defective Cells , 2010 .

[9]  M. Grace,et al.  Kinase requirements in human cells: V. Synthetic lethal interactions between p53 and the protein kinases SGK2 and PAK3 , 2010, Proceedings of the National Academy of Sciences.

[10]  F. Bauzon,et al.  Racing to block tumorigenesis after pRb loss: An innocuous point mutation wins with synthetic lethality , 2010, Cell cycle.

[11]  C. Croce,et al.  Roles of small RNAs in tumor formation. , 2010, Trends in molecular medicine.

[12]  A. Oza,et al.  Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer. , 2010 .

[13]  Jan Lubinski,et al.  Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  A. Ashworth,et al.  Biology-driven cancer drug development: back to the future , 2010, BMC Biology.

[15]  Y. Drew,et al.  Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors , 2010, Clinical Cancer Research.

[16]  P. Deloukas,et al.  Signatures of mutation and selection in the cancer genome , 2010, Nature.

[17]  A. Brandes,et al.  Trastuzumab and lapatinib beyond trastuzumab progression for metastatic breast cancer: strategies and pitfalls , 2010, Expert review of anticancer therapy.

[18]  M. O’Connor,et al.  ATM Deficiency Sensitizes Mantle Cell Lymphoma Cells to Poly(ADP-Ribose) Polymerase-1 Inhibitors , 2010, Molecular Cancer Therapeutics.

[19]  Tom Royce,et al.  A comprehensive catalogue of somatic mutations from a human cancer genome , 2010, Nature.

[20]  Marcel J T Reinders,et al.  Imaging , Diagnosis , Prognosis Clinical Cancer Research Integration of DNA Copy Number Alterations and Prognostic Gene Expression Signatures in Breast Cancer Patients , 2010 .

[21]  Makiko Takahashi,et al.  Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins , 2010, Breast Cancer Research.

[22]  A. Ashworth,et al.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.

[23]  D. Patt,et al.  Final Results of a Randomized Phase II Study Demonstrating Efficacy and Safety of BSI-201, a Poly (ADP-Ribose) Polymerase (PARP) Inhibitor, in Combination with Gemcitabine/Carboplatin (G/C) in Metastatic Triple Negative Breast Cancer (TNBC). , 2009 .

[24]  N. Hynes,et al.  Key signalling nodes in mammary gland development and cancer: Myc , 2009, Breast Cancer Research.

[25]  K. Flaherty,et al.  6BA Early efficacy signal demonstrated in advanced melanoma in a phase I trial of the oncogenic BRAF-selective inhibitor PLX4032 , 2009 .

[26]  Jung-Sik Kim,et al.  Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors , 2009, EMBO molecular medicine.

[27]  E. Brown,et al.  Tissue regenerative delays and synthetic lethality in adult mice upon combined deletion of ATR and p53 , 2009, Nature Genetics.

[28]  F. Couch,et al.  Edinburgh Research Explorer Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma , 2022 .

[29]  D. Geerts,et al.  Inactivation of CDK2 is synthetically lethal to MYCN over-expressing cancer cells , 2009, Proceedings of the National Academy of Sciences.

[30]  T. Pandita,et al.  Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair , 2009, Cell cycle.

[31]  D. Patt,et al.  Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  A. Tutt,et al.  Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  C. Palmieri,et al.  A 2009 update on the treatment of patients with hormone receptor-positive breast cancer. , 2009, Clinical breast cancer.

[34]  A. Ashworth,et al.  Tiling Path Genomic Profiling of Grade 3 Invasive Ductal Breast Cancers , 2009, Clinical Cancer Research.

[35]  M. Stockler,et al.  Third consensus on medical treatment of metastatic breast cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[36]  P. Borst,et al.  High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs , 2008, Proceedings of the National Academy of Sciences.

[37]  Y. Yin,et al.  PTEN: a new guardian of the genome , 2008, Oncogene.

[38]  S. Johnston,et al.  Platinum-based chemotherapy in triple-negative breast cancer. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[39]  Pier Paolo Pandolfi,et al.  Tenets of PTEN Tumor Suppression , 2008, Cell.

[40]  B. Karlan,et al.  Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. , 2008, Cancer research.

[41]  Jorge S. Reis-Filho,et al.  Resistance to therapy caused by intragenic deletion in BRCA2 , 2008, Nature.

[42]  F. Couch,et al.  Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers , 2008, Nature.

[43]  A. Joe,et al.  Oncogene addiction. , 2008, Cancer research.

[44]  Sreenath V. Sharma,et al.  Oncogene addiction: setting the stage for molecularly targeted cancer therapy. , 2007, Genes & development.

[45]  N. Curtin,et al.  PARP inhibitor development for systemic cancer targeting. , 2007, Anti-cancer agents in medicinal chemistry.

[46]  E. Kritikou.  Tumorigenesis: PTEN — a new guardian of the genome , 2007, Nature Reviews Cancer.

[47]  Michael B Yaffe,et al.  p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. , 2007, Cancer cell.

[48]  P. Pandolfi,et al.  Essential Role for Nuclear PTEN in Maintaining Chromosomal Integrity , 2007, Cell.

[49]  Ian Collins,et al.  New approaches to molecular cancer therapeutics , 2006, Nature chemical biology.

[50]  Robert Tibshirani,et al.  Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene‐expression subtypes of breast cancer , 2006, Genes, chromosomes & cancer.

[51]  J. Reis-Filho,et al.  Basal-like breast cancer and the BRCA1 phenotype , 2006, Oncogene.

[52]  Alan Ashworth,et al.  Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. , 2006, Cancer research.

[53]  W. Kaelin.  The Concept of Synthetic Lethality in the Context of Anticancer Therapy , 2005, Nature Reviews Cancer.

[54]  A. Ashworth,et al.  BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of poly (ADP-ribose) polymerase: An issue of potency , 2005, Cancer biology & therapy.

[55]  L. Symington.  Focus on recombinational DNA repair , 2005, EMBO reports.

[56]  Thomas Helleday,et al.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2005, Nature.

[57]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[58]  A. Ashworth,et al.  Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. , 2005, Cold Spring Harbor symposia on quantitative biology.

[59]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[60]  A. Ashworth,et al.  Hallmarks of 'BRCAness' in sporadic cancers , 2004, Nature Reviews Cancer.

[61]  G. de Murcia,et al.  The PARP superfamily , 2004, BioEssays : news and reviews in molecular, cellular and developmental biology.

[62]  Marc Nasoff,et al.  Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway. , 2004, Cancer cell.

[63]  M. McMillan.  History revisited. , 2004, The Australian journal of rural health.

[64]  Guan Chen,et al.  Potentiation of the antitumor activity of cisplatin in mice by 3-aminobenzamide and nicotinamide , 2004, Cancer Chemotherapy and Pharmacology.

[65]  R. Love,et al.  Oophorectomy for breast cancer: history revisited. , 2002, Journal of the National Cancer Institute.

[66]  I. Weinstein.  Addiction to Oncogenes--the Achilles Heal of Cancer , 2002, Science.

[67]  I. Smith,et al.  The development and clinical use of trastuzumab (Herceptin). , 2002, Endocrine-related cancer.

[68]  V. Heinemann.  Gemcitabine plus cisplatin for the treatment of metastatic breast cancer. , 2002, Clinical breast cancer.

[69]  Lyndsay N Harris,et al.  Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  B. Druker,et al.  Perspectives on the development of a molecularly targeted agent. , 2002, Cancer cell.

[71]  Y. Lu,et al.  Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). , 2001, Journal of the National Cancer Institute.

[72]  D. Wickerham,et al.  Findings from recent National Surgical Adjuvant Breast and Bowel Project adjuvant studies in stage I breast cancer. , 2001, Journal of the National Cancer Institute. Monographs.

[73]  T. Helleday,et al.  DNA double-strand breaks associated with replication forks are predominantly repaired by homologous recombination involving an exchange mechanism in mammalian cells. , 2001, Journal of molecular biology.

[74]  C. Sawyers,et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.

[75]  Larry L. Constantine,et al.  Back to the future , 2001, CACM.

[76]  C. Eng,et al.  PTEN suppresses breast cancer cell growth by phosphatase activity-dependent G1 arrest followed by cell death. , 1999, Cancer research.

[77]  N. Robert,et al.  Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  L. Hartwell,et al.  Integrating genetic approaches into the discovery of anticancer drugs. , 1997, Science.

[79]  M. Stratton.  Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases , 1997, The Lancet.

[80]  Alfred A. Boyd,et al.  Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2 , 1996, Nature Genetics.

[81]  Kenneth Offit,et al.  The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1% , 1996, Nature Genetics.

[82]  Q. Pan,et al.  The potentiation of the antitumor activity but not toxicity of bleomycin by 3-aminobenzamide. , 1989, The Journal of antibiotics.

[83]  B. Groner,et al.  Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. , 1988, Cancer research.

[84]  Susan M. Watanabe,et al.  An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity , 1984, Cell.

[85]  J. Lucchesi.  Synthetic lethality and semi-lethality among functionally related mutants of Drosophila melanfgaster. , 1968, Genetics.

[86]  T. Dobzhansky,et al.  Genetics of Natural Populations. Xiii. Recombination and Variability in Populations of Drosophila Pseudoobscura. , 1946, Genetics.